Literature DB >> 19536526

[11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging.

Donald F Smith1, Bo S Stork, Gregers Wegener, Mahmoud Ashkanian, Steen Jakobsen, Dirk Bender, Hélène Audrain, Karina H Vase, Søren B Hansen, Poul Videbech, Raben Rosenberg.   

Abstract

RATIONALE: Lack of benefit from antidepressant drug therapy is a major source of human suffering, affecting at least 25% of people with major depressive disorder. We want to know whether nonresponse to antidepressants can be linked to aberrant neuroreceptor binding.
OBJECTIVE: This study aims to assess the antidepressant binding in brain regions of depressed nonresponders compared with healthy controls.
MATERIALS AND METHODS: Healthy volunteers and depressed subjects who had failed to benefit from at least 2 antidepressant treatments were recruited by newspaper advertisements. All subjects had received no antidepressant medication for at least 2 months before positron emission tomography (PET) that was carried out with [11C]mirtazapine. Kinetic parameters of [11C]mirtazapine were determined from PET data in selected brain regions by the simplified reference tissue model.
RESULTS: Binding potentials of [11C]mirtazapine in cerebral cortical regions were lower in depressed nonresponders than in healthy controls. Removal rates of [11C]mirtazapine were higher in diencephalic regions of depressed nonresponders than in healthy controls.
CONCLUSIONS: PET neuroimaging with [11C]mirtazapine showed aberrant neuroreceptor binding in brain regions of depressed subjects who had failed to benefit from treatment with antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536526     DOI: 10.1007/s00213-009-1587-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

Review 1.  Diagnosis and definition of treatment-resistant depression.

Authors:  Maurizio Fava
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

Review 2.  Mirtazapine: a review of its clinical efficacy and tolerability.

Authors:  Armin Szegedi; Natascha Schwertfeger
Journal:  Expert Opin Pharmacother       Date:  2005-04       Impact factor: 3.889

3.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data.

Authors:  J G Sled; A P Zijdenbos; A C Evans
Journal:  IEEE Trans Med Imaging       Date:  1998-02       Impact factor: 10.048

4.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Authors:  J H Meyer; A A Wilson; N Ginovart; V Goulding; D Hussey; K Hood; S Houle
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

5.  Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.

Authors:  M J Millan; A Gobert; J M Rivet; A Adhumeau-Auclair; D Cussac; A Newman-Tancredi; A Dekeyne; J P Nicolas; F Lejeune
Journal:  Eur J Neurosci       Date:  2000-03       Impact factor: 3.386

Review 6.  The subgenual anterior cingulate cortex in mood disorders.

Authors:  Wayne C Drevets; Jonathan Savitz; Michael Trimble
Journal:  CNS Spectr       Date:  2008-08       Impact factor: 3.790

7.  The cost consequences of treatment-resistant depression.

Authors:  James M Russell; Kevin Hawkins; Ronald J Ozminkowski; Lucinda Orsini; William H Crown; Sean Kennedy; Stan Finkelstein; Ernst Berndt; A John Rush
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

8.  Receptor occupancy of mirtazapine determined by PET in healthy volunteers.

Authors:  Donald F Smith; Bo S Stork; Gregers Wegener; Steen Jakobsen; Dirk Bender; Hélène Audrain; Svend B Jensen; Søren B Hansen; Anders Rodell; Raben Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  2007-07-25       Impact factor: 4.530

Review 9.  Molecular tools for assessing human depression by positron emission tomography.

Authors:  Donald F Smith; Steen Jakobsen
Journal:  Eur Neuropsychopharmacol       Date:  2009-06-06       Impact factor: 4.600

10.  The Hamilton depression scale. Evaluation of objectivity using logistic models.

Authors:  P Bech; P Allerup; L F Gram; N Reisby; R Rosenberg; O Jacobsen; A Nagy
Journal:  Acta Psychiatr Scand       Date:  1981-03       Impact factor: 6.392

View more
  5 in total

1.  PET kinetics of radiolabeled antidepressant, [N-methyl-11C]mirtazapine, in the human brain.

Authors:  Ole L Munk; Donald F Smith
Journal:  EJNMMI Res       Date:  2011-12-15       Impact factor: 3.138

Review 2.  Application of cross-species PET imaging to assess neurotransmitter release in brain.

Authors:  Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood
Journal:  Psychopharmacology (Berl)       Date:  2015-04-30       Impact factor: 4.530

3.  Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.

Authors:  Donald F Smith; Steen Jakobsen
Journal:  Front Psychiatry       Date:  2013-03-04       Impact factor: 4.157

4.  Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk.

Authors:  Donald F Smith
Journal:  Front Psychiatry       Date:  2013-06-18       Impact factor: 4.157

Review 5.  PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives.

Authors:  Santosh Reddy Alluri; Sung Won Kim; Nora D Volkow; Kun-Eek Kil
Journal:  Molecules       Date:  2020-09-03       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.